|
|
Liver and Blood Lipid Changes after Antipsychotic Treatment for Schizophrenia |
CHEN Fang, PENG Shoulin, ZHOU Rong |
The Fourth People's Hospital of Chengdu, Sichuan Chengdu 610036, China |
|
|
Abstract Objective: To evaluate the efficacy of four kinds of antipsychotic treatment of schizophrenia and the treatment of liver and blood lipid changes. Method: 160 patients with schizophrenia who were enrolled from January 2015 to February 2016 were randomly divided into four groups: risperidone, quetiapine, olanzapine and aripiprazole group, respectively. Treatment efficiency, PANSS score before and after treatment, blood lipid levels, fatty liver and adverse drug reactions. Result: There was no significant difference between the four groups in the overall treatment rate and the overall incidence of fatty liver, and there was no statistical significance (P>0.05); After olanzapine treatment, the total score of PANSS group was significantly lower than that of quetiapine group; The levels of TC, TG and LDL in the quetiapine group were significantly higher than those in the other three groups, and the levels of TG and LDL in the olanzapine group were significantly lower than those in the risperidone group and the aripiprazole group; The incidence of other adverse reactions in quetiapine group was significantly higher than that of the other three groups, there was significant difference (P<0.01). Conclusion: Four kinds of dugs can be effective antipsychotics in the treatment of schizophrenia, but quetiapine on blood lipid influence, adverse reaction rate is the highest, while the relative efficacy of olanzapine on lipid stability, small adverse reaction rate is the lowest, so it can be recommended as the primary drug.
|
|
|
|
|
[1] 陶云海,申变红,朱春燕,等.精神分裂症患者长期应用抗精神病药治疗后肝脏及血脂变化情况分析[J].中华全科医学,2016,14(4):559~560.
[2] 陈方斌,孙剑,阎同军,等.奥氮平、阿立哌唑治疗精神分裂症后肝脏脂肪含量变化及其与胰岛素抵抗的关系[J].中国神经精神疾病杂志,2015,41(11):646~650.
[3] 张惠剑.精神分裂症患者长期服用氯氮平所致药源性脂肪肝分析[J].中国药物与临床,2015,15(1):123~124.
[4] 侯云跃,陈黎明,范林钰,等.不同抗精神病药物对精神分裂症患者临床疗效和糖脂代谢的影响[J].西部医学,2015,27(6):843~846.
[5] 张蕾,于文娟.非典型抗精神病药对肝脏的影响[J].中国临床药学杂志,2014,23(4):260~264.
[6] 刘春仙,张新风,刘胜皇.三种抗精神病药物对血糖血脂及体质量的不良影响[J].中国新药杂志,2015,24(12):1401~1403.
[7] 魏炎,黄六容,张程赪.丙戊酸镁缓释片联合新型抗精神病药对复发性躁狂症患者糖脂代谢的影响[J].临床心身疾病杂志,2014,20(2):5~7.
[8] 董乃琴.精神分裂症患者单用利培酮治疗对BMI指数、血脂及甲状腺激素水平的影响[J].中国现代医药杂志,2015,17(12):56~57.
[9] 陈方斌,陈琪,潘园园,等.奥氮平对首次发病精神分裂症患者肝脏脂肪含量的影响[J].中华精神科杂志,2014,47(4):237~241.
[10] 汪莉,隋云川,徐乐平,等.二甲双胍对奥氮平致体重增加精神分裂症患者肝脏脂肪含量的影响[J].中华精神科杂志,2016,49(1):36~41.
[11] 蒋燕,巢楠,徐乐平,等.奥氮平对精神分裂症患者肝脏脂肪含量的影响[J].临床军医杂志,2015,43(10):1077~1080.
[12] 龚科,郑俊兰.帕利哌酮缓释片对首发精神分裂症患者血脂代谢影响的研究[J].西部医学,2013,25(9):1386~1387,1390.
[13] 陶云海,申变红,朱春燕,等.精神分裂症患者长期应用抗精神病药治疗后肝脏及血脂变化情况分析[J].中华全科医学,2016,14(4):559~560,617.
[14] 张玉胜,贾继敏,张玉香等.二甲双胍联合运动疗法对抗精神病药致糖脂代谢紊乱患者血抵抗素和脂联素水平的影响[J].中国医药,2014,9(4):502~505. |
[1] |
. [J]. 河北医学, 2017, 23(9): 1540-1542. |
|
|
|
|